<> posologic adaptation of aminoglycosides treatments;<> adaptation posologique des traitements par aminoglycosides

Acta Clinica Belgica

Volumn 54, Issue SUPPL. 1, 1999, Pages 17-19

  Gougnard, Th ^a   Charlier, C ^a   Plomteux, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT;

AGED; CASE REPORT; COMPUTER PROGRAM; CONFERENCE PAPER; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; SEPTICEMIA;

EID: 0032916751     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol. 1995, 39: 597-603.
2. Bertino JS Jr, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet. 1994, 26: 71-81.
3. http://www.simkinrx.com/prodinfo%20Capcil.html
4. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother.1991, 27 (suppl C), 91-103.
5. Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997; 32: 30-57.
6. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet.1976; 1: 126-134.
7. Kaufmann GR, Vozeh S, Wenk M, Haefeli WE. Safety and efficacy of a two-compartment bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-bayesian one-compartment model. Ther Drug Monitoring.1998; 20: 172-180.
8. Nicolau DP, Wu AHB, Finocchiaro S et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monitoring 1996; 18: 263-266.
9. Nicolau DP, Freeman CD, Belliveau PL et al. Experience with a once-daily program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-655.
10. Binder L, Schiel X, Binder C et al. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. Clin Chem 1998; 44: 408-414.
11. Baer DM, Kotschi ML. On-line computer pharmacokinetics program: lessons learned from its failure. Clin Chem 1995; 41: 491-494.